Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 12/20 | 0.68 |
| ▸ | RARG | P13631 | 11/20 | 0.68 |
| ▸ | RARA | P10276 | 9/20 | 0.68 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.62 |
| ▸ | RXRA | P19793 | 11/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950477 | 1.00 | RARB (0.68) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4431065 | 1.00 | RARB (0.68) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4427154 | 1.00 | RARB (0.68) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL13950505 | 0.93 | RARB (0.57) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4421845 | 0.93 | RARB (0.57) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4427135 | 0.93 | RARB (0.57) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4421842 | 0.93 | RARB (0.57) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL4421849 | 0.93 | RARB (0.57) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL19698909 | 0.89 | RARB (0.56) | RARBRARGRARACYP26A1RXRA | |
| SCHEMBL26608150 | 0.88 | CYP26A1 (0.56) | RARBRARGRARACYP26A1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255937-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2023-08-17 | — | — | US | claimed |
| US-11471440-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2022-10-18 | — | — | US | claimed |
| US-20200345695-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2020-11-05 | — | — | US | claimed |
| US-10537556-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2020-01-21 | — | — | US | claimed |
| US-20190134002-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2019-05-09 | — | — | US | claimed |
| US-9492431-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2016-11-15 | — | — | US | claimed |
| US-20230255937-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230255937-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11471440-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2022-10-18 | — | — | US | disclosed |
| US-20200345695-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-2918290-B1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | UNIV YAMAGUCHI (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10537556-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2020-01-21 | — | — | US | disclosed |
| US-20190134002-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2019-05-09 | — | — | US | disclosed |
| US-9750721-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20170065562-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9492431-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2016-11-15 | — | — | US | disclosed |
| US-20150290172-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2918290-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | Yamaguchi University (JP) | 2015-09-16 | — | — | EP | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10537556-B2 | Therapeutic agent for keratoconjunctive disorders | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
| US-20150290172-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
| US-20230255937-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
| US-11471440-B2 | Therapeutic agent for keratoconjunctive disorders | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
| US-20170065562-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
| US-20190134002-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | RARB 3/4885RARG 1/4885RARA 4/4885 |
| US-20200345695-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | RARB 2/4885RARG 1/4885RARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.